Vtv Therapeutics Inc. · NASDAQ:VTVT
Vtv Therapeutics — Investor Presentation (March 2026)
25 slides from Vtv Therapeutics's investor presentation, Mar 10, 2026
Slide 1: Committed to Improving the Lives of People with Diabetes
1Nasdaq: VTVT Committed to Improving the Lives of People with Diabetes March 2026
Slide 2: Forward-Looking Statements
2 THE STATEMENTS MADE IN THIS PRESENTATION AND THE ACCOMPANYING ORAL COMMENTARY MAY INCLUDE FORWARD-LOOKING STATEMENTS REGARDING (I) THE DIABETES MARKET AND OTHER MARKETS, (II) THE DEVELOPMENT, CLINICAL TRIAL PROCESS, REGULATORY APPROVAL PROCESS AND ATTRIBUTES OF INVESTIGATIONAL AND MARKETED PRODUCT
Slide 3: Corporate Summary
3 1: Ebekozien O, et al. Longitudinal trends in glycemic outcomes and technology use for over 48,000 people with type 1 diabetes (2016–2022) from the T1D exchange quality improvement collaborative. Diab Technol Ther 2023 Nov;25(11):765-73.; 2: ADA Standard of Care 2026. Corporate Summary 01 Late-sta
Slide 4: Experienced Leadership
4 Experienced Leadership Carmen Valcarce, PhD Chief Scientific Officer Thomas Strack, MD Chief Medical Officer Dan Kirby SVP Strategic Operations PaulSekhri Chair, President &CEO Martin Lafontaine Chief Commercial Officer RichNelson Chief Business Officer Michael Tung, MD, MBA Chief Financial Office
Slide 5: Living with T1D is Like Driving on a Narrow and Dangerous Road
5 TOO MUCH INSULIN TOO LITTLE INSULIN Living with T1D is Like Driving on a Narrow and Dangerous Road No FDA-approved oral therapy to maintain glucose control for the 1.5M people living with type 1 diabetes in the U.S. Hyperglycemia: cumulative, long-term organ damage Hypoglycemia: immediate neurolog
Slide 6: The Challenge: Lowering Blood Glucose to Target While Preventing Hypoglycemia
6 Representative 7 Day CGM of a Patient with T1D1 The Challenge: Lowering Blood Glucose to Target While Preventing Hypoglycemia 1: Adapted from figure in Holt RI, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Associ
Slide 7: Cadisegliatin: A Large Opportunity in a Long-Underserved Market
7 Hypoglycemia is often the major limiting factor in the glycemic management of T1D3 Hypoglycemia is common in people with T1D and most have several mild to moderate events per week4 Hypoglycemic events range from life-disruptive to life- threatening ~9.9M people living with T1D globally, expected t
Slide 8: Cadisegliatin: Potential to be First Oral Adjunctive Therapy for T1D
8 Cadisegliatin: Potential to be First Oral Adjunctive Therapy for T1D 1: Internal studies – data on file; 2: Klein KR et al. The SimpliciT1 study: a randomized, double-blind, placebo-controlled phase 1b/2 adaptive study of TTP399, a hepatoselective glucokinase activator, for adjunctive treatment of
Slide 9: The Pancreas and Liver Maintain Glucose Homeostasis
9 The Pancreas and Liver Maintain Glucose Homeostasis Pancreas: Glucose Sensor and Controller • The pancreas continuously senses blood glucose and adjusts hormone release to keep blood glucose levels in a healthy range: • Beta cells secrete insulin → lowers blood glucose • Alpha cells secrete glucag
Slide 10: In People Who Do Not Live With Type 1 Diabetes
10 Insulin When blood sugar is low Stored glycogen is broken down into glucose and released to maintain glucose homeostasis Glucokinase (GK) Portal Vein The pancreas secretes insulin directly into the liver, which helps maintain sufficient glucokinase In People Who Do Not Live With Type 1 Diabetes:
Slide 11: In People Who Live With Type 1 Diabetes
11 When blood sugar is high Glucokinase activity is diminished due to low insulin, reducing glucose metabolism and glycogen storage Hypoglycemia Patient must take exogenous insulin Glucose Hypoglycemia Hyperglycemia Exogenous insulin must work its way through the body and cannot achieve sufficient l
Slide 12: Cadisegliatin Restores Glucose Metabolism in the Liver
12 Hyperglycemia Hypoglycemia When blood sugar is high Glucokinase activity is increased despite low insulin levels, increasing glucose metabolism and glycogen Glycogen Activates glucokinase in the liver, lowering blood glucose, improving glucose homeostasis & glycogen storage Cadisegliatin, a Gluco
Slide 13: Clinical Data for Cadisegliatin in T1D and T2D
13 AGATA Phase 2 Study in T2D1 Reduction of HbA1c by 0.9% vs. metformin (p<0.01) No difference to metformin with regards to hypoglycemia or hyperlipidemia over 6 months N = 190; US Study 1: Vella A, et al. Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase act
Slide 14: SimpliciT1 Phase 2 Trial in Patients with T1D
14 Improved Glycemic Control Fewer Hypoglycemic Events Δ = -0.36% p<0.001 Last Dose Δ = -50% p=0.04 Randomized, Double-Blind, Placebo (insulin alone) Controlled Two-Part Study of ~100 patients. A total of 49 patients in the treatment groups received 800mg daily of cadisegliatin. SimpliciT1 Phase 2 T
Slide 15: Cadisegliatin is Well-Tolerated Across People Living with T1D
15 Cadisegliatin is Well-Tolerated Across People Living with T1D1 1: Klein KR et al. The SimpliciT1 study: a randomized, double-blind, placebo-controlled phase 1b/2 adaptive study of TTP399, a hepatoselective glucokinase activator, for adjunctive treatment of type 1 diabetes. Diabetes Care. 2021 Apr
Slide 16: Cadisegliatin Does Not Adversely Impact Lipids in People Living with T1D
16 Cadisegliatin Does Not Adversely Impact Lipids in People Living with T1D1 1: Klein KR et al. The SimpliciT1 study: a randomized, double-blind, placebo-controlled phase 1b/2 adaptive study of TTP399, a hepatoselective glucokinase activator, for adjunctive treatment of type 1 diabetes. Diabetes Car
Slide 17: Phase 3 CATT1 Study Design
17 Cadisegliatin Phase 3 CATT1 Study* – Informed by FDA Advice and Published Guidance for Endpoint Selection, Exposure, and Population Criteria *NCT06334133; **US Food and Drug Administration. Diabetes Mellitus: Efficacy Endpoints for Clinical Trials Investigating Antidiabetic Drugs and Biological P
Slide 18: Investment Summary
18 Investment Summary 01 Late-stage asset Cadisegliatin, currently in Phase 3 development, has the potential to become the first oral adjunctive therapy for type 1 diabetes (T1D) in the U.S.; CATT1 enrollment completion expected 3Q 2026 02 Clinically de-risked Phase 1/2 studies in >500 participants
Slide 19: Small Molecule Portfolio
TV THERAPEUTICS Small Molecule Portfolio
Slide 20: Broader Portfolio Continues to Offer Additional Upside and Shareholder Value
20 Broader Portfolio Continues to Offer Additional Upside and Shareholder Value Pipeline candidates are under investigation, and the safety and efficacy have not been established. There is no guarantee that these products will receive health authority approval or become commercially available for th
Slide 21: Partnerships Provide Potential Independent Revenue Streams
21 Cadisegliatin (TTP399) GK Activator HPP737 PDE4 Inhibitor Azeliragon RAGE Antagonist Type 2 Diabetes Phase 2 initiation 2025 Middle East Psoriasis Ongoing Phase 3 trial China Pneumonia, Glioblastoma, Breast Cancer, Pancreatic Cancer Ongoing Phase 2 and Phase 3 trials US Certain countries in the M
Slide 22: Additional Programs: Differentiation in Large Market Opportunities
22 Additional Programs: Differentiation in Large Market Opportunities 1: Internal Studies – Data on File.; 2: Internal Studies – Data on File. TTP273 Oral GLP-1 Agonist Type 2 Diabetes/Obesity Phase 2 ready Negligible observed GI side effects1 Potential for improved tolerability, convenience and acc
Slide 23: TTP273: Oral Small Molecule GLP-1 Receptor Agonist
23 TTP273: Oral Small Molecule GLP-1 Receptor Agonist 1: https://www.cdc.gov/nchs/products/databriefs/db508.htm.; 2: Blue Health Intelligence, Real World Trends in GLP-1 Treatment Persistence and Prescribing for Weight Management, May 2024.; 3: Whitley HP, Trujillo JM, Neumiller JJ. Special Report:
Slide 24: HPP971/HPP3033: Nrf2/Bach1 Modulator Platform
24 Potential to advance multiple distinct compounds targeting reduced oxidative stress and inflammation HPP971/HPP3033: Nrf2/Bach1 Modulator Platform 1: Internal Studies – Data on File. Multiple non-electrophilic small- molecule compounds with distinct profiles Opportunity to advance multiple molecu
Slide 25: Thank You
25 Thank You ir@vtvtherapeutics.com
vTv Therapeutics — Investor Presentation (March 2026) on 6ix